Patents by Inventor Michael J. Tuvim

Michael J. Tuvim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION
    Publication number: 20240033348
    Abstract: Certain embodiments are directed to compositions and methods for attenuating allergic responses in a subject.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 1, 2024
    Inventors: Burton F. DICKEY, Michael J. TUVIM, Scott E. EVANS, Magnus HOOK, David P. HUSTON, Margarita MARTINEZ-MOCZYGEMBA, Brenton SCOTT
  • Methods and compositions for adaptive immune modulation
    Patent number: 11826422
    Abstract: Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: November 28, 2023
    Assignee: Board of Regents, the University of Texas System
    Inventors: Burton F. Dickey, Michael J. Tuvim, Scott E. Evans, Magnus Hook, David P. Huston, Margarita Martinez-Moczygemba, Brenton Scott
  • METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION
    Publication number: 20190269773
    Abstract: Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 5, 2019
    Inventors: Burton F. DICKEY, Michael J. TUVIM, Scott E. Evans, Magnus HOOK, David P. HUSTON, Margarita MARTINEZ-MOCZYGEMBA, Brenton SCOTT
  • Steroid-sparing effects of beta-adrenergic inverse agonists and uses thereof
    Patent number: 9730889
    Abstract: Provided herein is a pharmaceutical composition combination which comprises (a) a corticosteroid and (b) b-adrenergic receptor antagonist characterised in that active ingredients (a) and (b) form part of a single composition. Further provided is a method of treating a human or animal patient suffering from or susceptible to a respiratory disease or condition, said method comprises simultaneously, concurrently, separately or sequentially administering to the patient an effective amount of a b-adrenergic receptor antagonist and a corticosteroid.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: August 15, 2017
    Assignee: University of Houston System
    Inventors: Richard A. Bond, Burton F. Dickey, Michael J. Tuvim
  • Steroid-Sparing Effects of Beta-Adrenergic Inverse Agonists and Uses Thereof
    Publication number: 20120289488
    Abstract: Provided herein is a pharmaceutical composition combination which comprises (a) a corticosteroid and (b) b-adrenergic receptor antagonist characterised in that active ingredients (a) and (b) form part of a single composition. Further provided is a method of treating a human or animal patient suffering from or susceptible to a respiratory disease or condition, said method comprises simultaneously, concurrently, separately or sequentially administering to the patient an effective amount of a b-adrenergic receptor antagonist and a corticosteroid.
    Type: Application
    Filed: May 8, 2012
    Publication date: November 15, 2012
    Inventors: Richard A. Bond, Burton F. Dickey, Michael J. Tuvim